<?xml version="1.0" encoding="UTF-8"?>
<rr:ResultsReport xmlns:rr="http://integration.foundationmedicine.com/reporting" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd">
  <rr:CustomerInformation>
    <rr:ReferenceID>01-2023-00030459</rr:ReferenceID>
    <rr:CSN />
    <rr:TRF>ORD-1655856-01</rr:TRF>
    <rr:MRN>29696660</rr:MRN>
    <rr:PhysicianId>109266</rr:PhysicianId>
    <rr:NPI />
  </rr:CustomerInformation>
  <rr:ResultsPayload>
    <FinalReport xmlns:xsd="http://www.w3.org/2001/XMLSchema" StagingId="1336865" clinicalId="1338212" xsi:noNamespaceSchemaLocation="http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd">
      <Application>
        <ApplicationSettings>
          <ApplicationSetting>
            <Name>Statement</Name>
            <Value />
          </ApplicationSetting>
        </ApplicationSettings>
      </Application>
      <DemographicCorrectionDate />
      <ReportId>ORD-1655856-01</ReportId>
      <SampleName>US1579280.01</SampleName>
      <Version>0</Version>
      <Sample>
        <FM_Id>ORD-1655856-01</FM_Id>
        <SampleId>US1579280.01</SampleId>
        <BlockId>CCH 10/10/1949</BlockId>
        <TRFNumber>ORD-1655856-01</TRFNumber>
        <TestType>FoundationOneLiquidDx</TestType>
        <SpecFormat>Tube Set</SpecFormat>
        <ReceivedDate>2023-06-19</ReceivedDate>
        <processSites>
          <processSite address="150 Second St., 1st Floor, Cambridge, MA 02141" cliaNumber="22D2027531" locationID="1" locationName="Cambridge" processID="1" processName="Extracted DNA" />
          <processSite address="150 Second St., 1st Floor, Cambridge, MA 02141" cliaNumber="22D2027531" locationID="1" locationName="Cambridge" processID="1" processName="LC" />
        </processSites>
      </Sample>
      <PMI>
        <ReportId>ORD-1655856-01</ReportId>
        <MRN>29696660</MRN>
        <FullName>Huang, Chiu-Chu</FullName>
        <FirstName>Chiu-Chu</FirstName>
        <LastName>Huang</LastName>
        <SubmittedDiagnosis>Bile duct extrahepatic cholangiocarcinoma</SubmittedDiagnosis>
        <Gender>Female</Gender>
        <DOB>1949-10-10</DOB>
        <OrderingMD>Yeh, Yi-Chen</OrderingMD>
        <OrderingMDId>109266</OrderingMDId>
        <Pathologist>Not Provided</Pathologist>
        <CopiedPhysician1 />
        <MedFacilName>Taipei Veterans General Hospital</MedFacilName>
        <MedFacilID>205872</MedFacilID>
        <SpecSite>Blood</SpecSite>
        <CollDate>2023-06-15</CollDate>
        <ReceivedDate>2023-06-19</ReceivedDate>
        <CountryOfOrigin>TW</CountryOfOrigin>
      </PMI>
      <PertinentNegatives />
      <Summaries alterationCount="16" clinicalTrialCount="0" resistiveCount="0" sensitizingCount="0" />
      <VariantProperties>
        <VariantProperty geneName="AR" isVUS="true" variantName="T756N" />
        <VariantProperty geneName="BRAF" isVUS="true" variantName="D22N" />
        <VariantProperty geneName="CSF1R" isVUS="true" variantName="T75I" />
        <VariantProperty geneName="FANCG" isVUS="true" variantName="R141C" />
        <VariantProperty geneName="FLT3" isVUS="true" variantName="T715A" />
        <VariantProperty geneName="KMT2D (MLL2)" isVUS="true" variantName="V1561G" />
        <VariantProperty geneName="MLH1" isVUS="true" variantName="R217C" />
        <VariantProperty geneName="NKX2-1" isVUS="true" variantName="A339V" />
        <VariantProperty geneName="PTEN" isVUS="true" variantName="K260R" />
        <VariantProperty geneName="TBX3" isVUS="true" variantName="A562V" />
        <VariantProperty geneName="TYRO3" isVUS="true" variantName="S103R" />
      </VariantProperties>
      <priorTests />
      <Genes>
        <Gene>
          <Name>Blood Tumor Mutational Burden</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>01</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="01" />
              </AlterationProperties>
              <Interpretation>Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide-based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered. Average bTMB levels in solid tumors other than NSCLC have not been evaluated (PubMed, Mar 2023). Published data investigating the prognostic implications of bTMB levels in biliary tract cancer are limited (PubMed, Jul 2022). Although cases with hypermutated biliary tract cancer were enriched in a subgroup with poor prognosis in 1 study (Nakamura et al., 2015; 26258846), TMB-high (≥10 mut/Mb) status in biliary adenocarcinoma not treated with immunotherapy was not significantly associated with OS in another study, in which patients with TMB-high tumors experienced numerically longer OS compared with patients with TMB-low tumors (11.5 vs. 8.4 months, adjusted HR=0.65) (Shao et al., 2020; 33119110). On the basis of clinical evidence in solid tumors, increased blood tumor mutational burden (bTMB) may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti-PD-1 (Schenker et al., 2022; AACR Abstract CT022, Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti-PD-1/CTLA4 therapies (Schenker et al., 2022; AACR Abstract CT022, Saori et al., 2021; ESMO Abstract 80P), anti-PD-L1/CTLA4 therapies (Chen et al., 2020; 32379280, Loree et al., 2021; ASCO GI Abstract 61, Li et al., 2020; ASCO Abstract 6511, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). A Phase 2 multi-solid-tumor trial showed that bTMB ≥16 Muts/Mb (as measured by this assay) was associated with improved survival from treatment with a PD-1 inhibitor alone or in combination with a CTLA-4 inhibitor (Schenker et al., 2022; AACR Abstract CT022). In non-small cell lung cancer (NSCLC), multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single-agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 Muts/Mb-16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). In head and neck squamous cell carcinoma (HNSCC), a Phase 3 trial showed that bTMB ≥16 Muts/Mb (approximate equivalency ≥8 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD-L1 inhibitor alone or in combination with a CTLA-4 inhibitor (Li et al., 2020; ASCO Abstract 6511). In colorectal cancer (CRC), a Phase 2 study showed that bTMB TMB ≥28 Muts/Mb (approximate equivalency ≥14 Muts/Mb as measured by this assay) was associated with improved OS from a PD-L1 inhibitor alone or in combination with a CTLA-4 inhibitor (Loree et al., 2021; ASCO GI Abstract 61, Chen et al., 2020; 32379280).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>Microsatellite status</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>Cannot Be Determined</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="Cannot Be Determined" />
              </AlterationProperties>
              <Interpretation>Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI-H is infrequent in cholangiocarcinoma, reported in 1% of samples (Javle et al., 2019; ASCO Abstract 4087). A non-zero level of MSI has been reported in 18-49% of cholangiocarcinoma cases (Momoi et al., 2001; 11580146, Limpaiboon et al., 2002; 12175538, Liu et al., 2002; 12402306, Liengswangwong et al., 2003; 14506736), although the studies did not specify what fraction of cases were MSI-H. A higher frequency of MSI (63%) was reported in patients with intrahepatic cholangiocarcinoma associated with exposure to Thorotrast (Liu et al., 2002; 12402306). No significant difference in median OS or prognosis was found in microsatellite instability-high (MSI-H) gallbladder carcinomas when compared with microsatellite-stable (MSS) cases (Moy et al., 2015; 25680569, Roa et al., 2005; 15692793, Rashid et al., 2002; 12374683). One study reported that MSI is associated with poor prognosis in liver fluke-related cholangiocarcinoma (Limpaiboon et al., 2002; 12175538). On the basis of clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD-1-targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), retifanlimab, and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Shitara et al., 2022; 35322232, Andre et al., 2022; ASCO GI Abstract 244, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143, Berton et al., 2021; SITC Abstract 956), as well as PD-L1-targeting agents atezolizumab, avelumab, and durvalumab (alone or in combination with tremelimumab) (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92, Pietrantonio et al., 2023; ASCO GI Abstract 358, Lee et al., 2023; ASCO GI abstract 401, Rubinstein et al., 2022; 36512912, Marie et al., 2021; 33811152). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>TP53</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>splice site 783-1G&gt;A</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="0.52" isEquivocal="false" name="splice site 783-1G&gt;A" />
              </AlterationProperties>
              <Interpretation>Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). Inactivation of p53, through mutation, deletion, or loss of heterozygosity (LOH), has been observed in 25-63% of gallbladder carcinomas and 10-61% of cholangiocarcinomas (Li et al., 2014; 24997986, Ross et al., 2014; 24563076, Jiao et al., 2013; 24185509, Chan-On et al., 2013; 24185513, Borger et al., 2012; 22180306, Suto et al., 2000; 10738270, Ong et al., 2012; 22561520, Javle et al., 2016; 27622582, Nakamura et al., 2015; 26258846, Nault and Zucman-Rossi, 2011; 21538283). TP53 mutations occur more frequently in tumors caused by liver fluke (O. viverrini) infection (40%) than in cholangiocarcinoma cases not related to infection (9%) (Chan-On et al., 2013; 24185513). Aberrant TP53 expression, which is indicative of TP53 dysregulation, has been observed in 20–62% of gallbladder carcinomas and 25% (5/20) of cholangiocarcinomas (Won et al., 2010; 20955617, Chaube et al., 2006; 16686942, Chuang et al., 2004; 15573254). Data regarding the prognostic significance of TP53 mutation in cholangiocarcinoma are conflicting (Ruzzenente et al., 2016; 26717940, Xiaofang et al., 2012; 22230750, Ajiki et al., 1996; 8799388, Saetta, 2006; 16724348, Guo et al., 2014; 24746206, Boerner et al., 2021; 33765338, Conci et al., 2020; 32020551, Simbolo et al., 2018; 29740198, Churi et al., 2014; 25536104). Overexpression of p53 protein has been associated with reduced patient survival in poorly differentiated gallbladder adenocarcinomas and biliary tract cancers (Lee and Pirdas, 1995; 7567135, Ahrendt et al., 2000; 11180865); however, another study did not find such a correlation (Ajiki et al., 1996; 8799388). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633) or p53 gene therapy such as SGT53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628, Leung et al., 2021; ASCO Abstract 4139). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum-refractory TP53-mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum-refractory TP53-mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53-mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53-mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4-C trial for patients with TP53- and RAS-mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT-53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53-positive high-grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29) (Park et al., 2022; 36084396). One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li-Fraumeni syndrome (ClinVar, Apr 2023)(Landrum et al., 2018; 29165669). Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li-Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna-Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
            <Alteration>
              <Name>G244D</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="0.21" isEquivocal="false" name="G244D" />
              </AlterationProperties>
              <Interpretation>Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). Inactivation of p53, through mutation, deletion, or loss of heterozygosity (LOH), has been observed in 25-63% of gallbladder carcinomas and 10-61% of cholangiocarcinomas (Li et al., 2014; 24997986, Ross et al., 2014; 24563076, Jiao et al., 2013; 24185509, Chan-On et al., 2013; 24185513, Borger et al., 2012; 22180306, Suto et al., 2000; 10738270, Ong et al., 2012; 22561520, Javle et al., 2016; 27622582, Nakamura et al., 2015; 26258846, Nault and Zucman-Rossi, 2011; 21538283). TP53 mutations occur more frequently in tumors caused by liver fluke (O. viverrini) infection (40%) than in cholangiocarcinoma cases not related to infection (9%) (Chan-On et al., 2013; 24185513). Aberrant TP53 expression, which is indicative of TP53 dysregulation, has been observed in 20–62% of gallbladder carcinomas and 25% (5/20) of cholangiocarcinomas (Won et al., 2010; 20955617, Chaube et al., 2006; 16686942, Chuang et al., 2004; 15573254). Data regarding the prognostic significance of TP53 mutation in cholangiocarcinoma are conflicting (Ruzzenente et al., 2016; 26717940, Xiaofang et al., 2012; 22230750, Ajiki et al., 1996; 8799388, Saetta, 2006; 16724348, Guo et al., 2014; 24746206, Boerner et al., 2021; 33765338, Conci et al., 2020; 32020551, Simbolo et al., 2018; 29740198, Churi et al., 2014; 25536104). Overexpression of p53 protein has been associated with reduced patient survival in poorly differentiated gallbladder adenocarcinomas and biliary tract cancers (Lee and Pirdas, 1995; 7567135, Ahrendt et al., 2000; 11180865); however, another study did not find such a correlation (Ajiki et al., 1996; 8799388). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633) or p53 gene therapy such as SGT53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628, Leung et al., 2021; ASCO Abstract 4139). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum-refractory TP53-mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum-refractory TP53-mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53-mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53-mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4-C trial for patients with TP53- and RAS-mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT-53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53-positive high-grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29) (Park et al., 2022; 36084396). One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li-Fraumeni syndrome (ClinVar, Apr 2023)(Landrum et al., 2018; 29165669). Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li-Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna-Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>Tumor Fraction</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>Elevated Tumor Fraction Not Detected</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="Elevated Tumor Fraction Not Detected" />
              </AlterationProperties>
              <Interpretation>Tumor fraction provides an estimate of the percentage of ctDNA present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single-nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with elevated tumor fraction values have high circulating-tumor DNA (ctDNA) content, and thus higher sensitivity for identifying genomic alterations. Such specimens are at a lower risk of false negative results. However, if elevated tumor fraction is not detected, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
      </Genes>
      <Trials />
      <References>
        <Reference number="0">
          <ReferenceId>26337942</ReferenceId>
          <FullCitation>Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="1">
          <ReferenceId>21081928</ReferenceId>
          <FullCitation>You JF, et al. Br. J. Cancer (2010) pmid: 21081928</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="2">
          <ReferenceId>24623249</ReferenceId>
          <FullCitation>Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="3">
          <ReferenceId>11580146</ReferenceId>
          <FullCitation>Momoi H, et al. J. Hepatol. (2001) pmid: 11580146</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="4">
          <ReferenceId>12175538</ReferenceId>
          <FullCitation>Limpaiboon T, et al. Cancer Lett. (2002) pmid: 12175538</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="5">
          <ReferenceId>12402306</ReferenceId>
          <FullCitation>Liu D, et al. Int. J. Cancer (2002) pmid: 12402306</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="6">
          <ReferenceId>14506736</ReferenceId>
          <FullCitation>Liengswangwong U, et al. Int. J. Cancer (2003) pmid: 14506736</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="7">
          <ReferenceId>25680569</ReferenceId>
          <FullCitation>Moy AP, et al. Virchows Arch. (2015) pmid: 25680569</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="8">
          <ReferenceId>15692793</ReferenceId>
          <FullCitation>Roa JC, et al. J. Gastroenterol. (2005) pmid: 15692793</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="9">
          <ReferenceId>12374683</ReferenceId>
          <FullCitation>Rashid A, et al. Clin. Cancer Res. (2002) pmid: 12374683</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="10">
          <ReferenceId>17204026</ReferenceId>
          <FullCitation>Histopathology (2007) pmid: 17204026</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="11">
          <ReferenceId>25949894</ReferenceId>
          <FullCitation>Lal N, et al. Oncoimmunology (2015) pmid: 25949894</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="12">
          <ReferenceId>28734759</ReferenceId>
          <FullCitation>Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="13">
          <ReferenceId>29355075</ReferenceId>
          <FullCitation>Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="14">
          <ReferenceId>35322232</ReferenceId>
          <FullCitation>Shitara K, et al. Nature (2022) pmid: 35322232</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="15">
          <ReferenceId>23169436</ReferenceId>
          <FullCitation>Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="16">
          <ReferenceId>26028255</ReferenceId>
          <FullCitation>Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="17">
          <ReferenceId>25765070</ReferenceId>
          <FullCitation>Rizvi NA, et al. Science (2015) pmid: 25765070</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="18">
          <ReferenceId>33001143</ReferenceId>
          <FullCitation>Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="19">
          <ReferenceId>36512912</ReferenceId>
          <FullCitation>Rubinstein MM, et al. Gynecol Oncol (2022) pmid: 36512912</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="20">
          <ReferenceId>33811152</ReferenceId>
          <FullCitation>Kanikarla Marie P, et al. Clin Cancer Res (2021) pmid: 33811152</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="21">
          <ReferenceId>19935675</ReferenceId>
          <FullCitation>Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="22">
          <ReferenceId>18410249</ReferenceId>
          <FullCitation>Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="23">
          <ReferenceId>12826609</ReferenceId>
          <FullCitation>Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="24">
          <ReferenceId>20978130</ReferenceId>
          <FullCitation>Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="25">
          <ReferenceId>28472496</ReferenceId>
          <FullCitation>Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="26">
          <ReferenceId>17690113</ReferenceId>
          <FullCitation>Yamada H, et al. Carcinogenesis (2007) pmid: 17690113</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="27">
          <ReferenceId>24997986</ReferenceId>
          <FullCitation>Li M, et al. Nat. Genet. (2014) pmid: 24997986</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="28">
          <ReferenceId>24563076</ReferenceId>
          <FullCitation>Ross JS, et al. Oncologist (2014) pmid: 24563076</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="29">
          <ReferenceId>24185509</ReferenceId>
          <FullCitation>Jiao Y, et al. Nat. Genet. (2013) pmid: 24185509</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="30">
          <ReferenceId>24185513</ReferenceId>
          <FullCitation>Chan-On W, et al. Nat. Genet. (2013) pmid: 24185513</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="31">
          <ReferenceId>22180306</ReferenceId>
          <FullCitation>Borger DR, et al. Oncologist (2012) pmid: 22180306</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="32">
          <ReferenceId>10738270</ReferenceId>
          <FullCitation>Suto T, et al. J Surg Oncol (2000) pmid: 10738270</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="33">
          <ReferenceId>22561520</ReferenceId>
          <FullCitation>Ong CK, et al. Nat. Genet. (2012) pmid: 22561520</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="34">
          <ReferenceId>27622582</ReferenceId>
          <FullCitation>Javle M, et al. Cancer (2016) pmid: 27622582</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="35">
          <ReferenceId>26258846</ReferenceId>
          <FullCitation>Nakamura H, et al. Nat. Genet. (2015) pmid: 26258846</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="36">
          <ReferenceId>21538283</ReferenceId>
          <FullCitation>Nault JC, et al. Semin. Liver Dis. (2011) pmid: 21538283</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="37">
          <ReferenceId>20955617</ReferenceId>
          <FullCitation>Won HS, et al. BMC Cancer (2010) pmid: 20955617</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="38">
          <ReferenceId>16686942</ReferenceId>
          <FullCitation>Chaube A, et al. BMC Cancer (2006) pmid: 16686942</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="39">
          <ReferenceId>15573254</ReferenceId>
          <FullCitation>Chuang SC, et al. World J Surg (2004) pmid: 15573254</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="40">
          <ReferenceId>26717940</ReferenceId>
          <FullCitation>Ruzzenente A, et al. Ann. Surg. Oncol. (2016) pmid: 26717940</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="41">
          <ReferenceId>22230750</ReferenceId>
          <FullCitation>Xiaofang L, et al. World J Surg Oncol (2012) pmid: 22230750</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="42">
          <ReferenceId>8799388</ReferenceId>
          <FullCitation>Ajiki T, et al. Hepatogastroenterology () pmid: 8799388</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="43">
          <ReferenceId>16724348</ReferenceId>
          <FullCitation>J Surg Oncol (2006) pmid: 16724348</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="44">
          <ReferenceId>24746206</ReferenceId>
          <FullCitation>Guo R, et al. Hum. Pathol. (2014) pmid: 24746206</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="45">
          <ReferenceId>33765338</ReferenceId>
          <FullCitation>Boerner T, et al. Hepatology (2021) pmid: 33765338</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="46">
          <ReferenceId>32020551</ReferenceId>
          <FullCitation>Conci S, et al. Updates Surg (2020) pmid: 32020551</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="47">
          <ReferenceId>29740198</ReferenceId>
          <FullCitation>Simbolo M, et al. Sci Rep (2018) pmid: 29740198</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="48">
          <ReferenceId>25536104</ReferenceId>
          <FullCitation>Churi CR, et al. PLoS ONE (2014) pmid: 25536104</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="49">
          <ReferenceId>7567135</ReferenceId>
          <FullCitation>Lee CS, et al. Pathology (1995) pmid: 7567135</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="50">
          <ReferenceId>11180865</ReferenceId>
          <FullCitation>Ahrendt SA, et al. J Hepatobiliary Pancreat Surg (2000) pmid: 11180865</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="51">
          <ReferenceId>20107315</ReferenceId>
          <FullCitation>Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="52">
          <ReferenceId>21799033</ReferenceId>
          <FullCitation>Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="53">
          <ReferenceId>21389100</ReferenceId>
          <FullCitation>Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="54">
          <ReferenceId>25504633</ReferenceId>
          <FullCitation>Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="55">
          <ReferenceId>12489850</ReferenceId>
          <FullCitation>Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="56">
          <ReferenceId>11713371</ReferenceId>
          <FullCitation>Xu L, et al. Mol. Med. (2001) pmid: 11713371</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="57">
          <ReferenceId>23470564</ReferenceId>
          <FullCitation>Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="58">
          <ReferenceId>25240597</ReferenceId>
          <FullCitation>Kim SS, et al. Nanomedicine (2015) pmid: 25240597</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="59">
          <ReferenceId>27357628</ReferenceId>
          <FullCitation>Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="60">
          <ReferenceId>27601554</ReferenceId>
          <FullCitation>Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="61">
          <ReferenceId>27998224</ReferenceId>
          <FullCitation>Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="62">
          <ReferenceId>31315834</ReferenceId>
          <FullCitation>Lee J, et al. Cancer Discov (2019) pmid: 31315834</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="63">
          <ReferenceId>29535125</ReferenceId>
          <FullCitation>Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="64">
          <ReferenceId>34538072</ReferenceId>
          <FullCitation>Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="65">
          <ReferenceId>36084396</ReferenceId>
          <FullCitation>Park H, et al. ESMO Open (2022) pmid: 36084396</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="66">
          <ReferenceId>29165669</ReferenceId>
          <FullCitation>Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="67">
          <ReferenceId>26014290</ReferenceId>
          <FullCitation>Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="68">
          <ReferenceId>23355100</ReferenceId>
          <FullCitation>Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="69">
          <ReferenceId>11219776</ReferenceId>
          <FullCitation>Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="70">
          <ReferenceId>9006316</ReferenceId>
          <FullCitation>Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="71">
          <ReferenceId>19204208</ReferenceId>
          <FullCitation>Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="72">
          <ReferenceId>12672316</ReferenceId>
          <FullCitation>Lalloo F, et al. Lancet (2003) pmid: 12672316</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="73">
          <ReferenceId>31050713</ReferenceId>
          <FullCitation>Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="74">
          <ReferenceId>25426837</ReferenceId>
          <FullCitation>Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="75">
          <ReferenceId>25426838</ReferenceId>
          <FullCitation>Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="76">
          <ReferenceId>25326804</ReferenceId>
          <FullCitation>Xie M, et al. Nat. Med. (2014) pmid: 25326804</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="77">
          <ReferenceId>28669404</ReferenceId>
          <FullCitation>Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="78">
          <ReferenceId>29678827</ReferenceId>
          <FullCitation>Severson EA, et al. Blood (2018) pmid: 29678827</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="79">
          <ReferenceId>29420212</ReferenceId>
          <FullCitation>Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="80">
          <ReferenceId>30504320</ReferenceId>
          <FullCitation>Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="81">
          <ReferenceId>32269342</ReferenceId>
          <FullCitation>Chabon JJ, et al. Nature (2020) pmid: 32269342</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="82">
          <ReferenceId>31768066</ReferenceId>
          <FullCitation>Razavi P, et al. Nat. Med. (2019) pmid: 31768066</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="83">
          <ReferenceId>15748635</ReferenceId>
          <FullCitation>Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="84">
          <ReferenceId>23875803</ReferenceId>
          <FullCitation>Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="85">
          <ReferenceId>12379884</ReferenceId>
          <FullCitation>Pfeifer GP, et al. Oncogene (2002) pmid: 12379884</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="86">
          <ReferenceId>24336570</ReferenceId>
          <FullCitation>Johnson BE, et al. Science (2014) pmid: 24336570</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="87">
          <ReferenceId>29452419</ReferenceId>
          <FullCitation>Choi S, et al. Neuro-oncology (2018) pmid: 29452419</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="88">
          <ReferenceId>23636398</ReferenceId>
          <FullCitation>Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="89">
          <ReferenceId>23447401</ReferenceId>
          <FullCitation>Briggs S, et al. J. Pathol. (2013) pmid: 23447401</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="90">
          <ReferenceId>24583393</ReferenceId>
          <FullCitation>Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="91">
          <ReferenceId>22810696</ReferenceId>
          <FullCitation>Nature (2012) pmid: 22810696</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="92">
          <ReferenceId>25568919</ReferenceId>
          <FullCitation>Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="93">
          <ReferenceId>30082870</ReferenceId>
          <FullCitation>Gandara DR, et al. Nat. Med. (2018) pmid: 30082870</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="94">
          <ReferenceId>30816954</ReferenceId>
          <FullCitation>Wang Z, et al. JAMA Oncol (2019) pmid: 30816954</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="95">
          <ReferenceId>32102950</ReferenceId>
          <FullCitation>Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="96">
          <ReferenceId>33119110</ReferenceId>
          <FullCitation>Shao C, et al. JAMA Netw Open (2020) pmid: 33119110</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="97">
          <ReferenceId>35274716</ReferenceId>
          <FullCitation>Sturgill EG, et al. Oncologist (2022) pmid: 35274716</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="98">
          <ReferenceId>32379280</ReferenceId>
          <FullCitation>Chen EX, et al. JAMA Oncol (2020) pmid: 32379280</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="99">
          <ReferenceId>32271377</ReferenceId>
          <FullCitation>Rizvi NA, et al. JAMA Oncol (2020) pmid: 32271377</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="100">
          <ReferenceId>33355200</ReferenceId>
          <FullCitation>Si H, et al. Clin Cancer Res (2021) pmid: 33355200</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="101">
          <ReferenceId>34800700</ReferenceId>
          <FullCitation>Leighl NB, et al. J Thorac Oncol (2022) pmid: 34800700</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="102">
          <ReferenceId>31602320</ReferenceId>
          <FullCitation>Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="103">
          <ReferenceId>32757294</ReferenceId>
          <FullCitation>Zhang EW, et al. Cancer (2020) pmid: 32757294</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="104">
          <ReferenceId>30833418</ReferenceId>
          <FullCitation>Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="105">
          <ReferenceId>24553385</ReferenceId>
          <FullCitation>Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="106">
          <ReferenceId>30400802</ReferenceId>
          <FullCitation>Lapin M, et al. J Transl Med (2018) pmid: 30400802</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="107">
          <ReferenceId>30131550</ReferenceId>
          <FullCitation>Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="108">
          <ReferenceId>30385733</ReferenceId>
          <FullCitation>Choudhury AD, et al. JCI Insight (2018) pmid: 30385733</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="109">
          <ReferenceId>29298117</ReferenceId>
          <FullCitation>Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="110">
          <ReferenceId>30793095</ReferenceId>
          <FullCitation>Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="111">
          <ReferenceId>31059681</ReferenceId>
          <FullCitation>Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="112">
          <ReferenceId>28187169</ReferenceId>
          <FullCitation>Fan G, et al. PLoS ONE (2017) pmid: 28187169</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="113">
          <ReferenceId>30923679</ReferenceId>
          <FullCitation>Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="114">
          <ReferenceId>30093454</ReferenceId>
          <FullCitation>Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="115">
          <ReferenceId>30860573</ReferenceId>
          <FullCitation>Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="116">
          <ReferenceId>28450425</ReferenceId>
          <FullCitation>Goodall J, et al. Cancer Discov (2017) pmid: 28450425</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="117">
          <ReferenceId>29330207</ReferenceId>
          <FullCitation>Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207</FullCitation>
          <Include>true</Include>
        </Reference>
      </References>
      <Signatures>
        <Signature>
          <ServerTime>2023-06-26 16:55:35</ServerTime>
          <OpName>Brennan Decker, M.D., Ph.D. | Julia Elvin, M.D., Ph.D., Laboratory Director</OpName>
          <Text>Brennan Decker, M.D., Ph.D. | Julia Elvin, M.D., Ph.D., Laboratory Director</Text>
        </Signature>
      </Signatures>
      <reportProperties>
        <reportProperty identifier="QualityControlMetrics" key="MedianCoverageValue">
          <value>N/A</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="TumorMutationBurdenScore">
          <value>Units Not Reported</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="MicrosatelliteStatusScore">
          <value>0 fraction-unstable-loci</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="LossOfHeterozygosityScore">
          <value>Units Not Reported</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="BloodTumorMutationalBurdenScore">
          <value>1 Muts/Mb</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="TumorFractionScore">
          <value>0%</value>
        </reportProperty>
      </reportProperties>
      <comments />
      <AAC>
        <Amendmends />
      </AAC>
    </FinalReport>
    <variant-report xmlns="http://foundationmedicine.com/compbio/variant-report-external" disease="BILE DUCT" disease-ontology="Bile duct extrahepatic cholangiocarcinoma" flowcell-analysis="2000029664" gender="female" pathology-diagnosis="common bile duct adenocarcinoma" pipeline-version="v3.23.0" purity-assessment="5.01" specimen="ORD-1655856-01*US1579280.01" study="CLINICAL-F1LCDx" test-request="ORD-1655856-01" test-type="FoundationOneLiquidDx" tissue-of-origin="Blood" xsi:schemaLocation="http://foundationmedicine.com/compbio/variant-report-external http://integration.foundationmedicine.com/reporting/variant-report-external-2.2.xsd">
      <samples>
        <sample bait-set="AB1" name="SQ-US1579280.01-1" nucleic-acid-type="DNA" />
      </samples>
      <quality-control status="Pass" />
      <short-variants>
        <short-variant allele-fraction="0.0052" cds-effect="783-1G&gt;A" depth="5623" equivocal="false" functional-effect="splice" gene="TP53" percent-reads="0.52" position="chr17:7577156" protein-effect="splice site 783-1G&gt;A" status="likely" strand="-" transcript="NM_000546">
          <dna-evidence sample="SQ-US1579280.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.4894" cds-effect="1685C&gt;T" depth="2035" equivocal="false" functional-effect="missense" gene="TBX3" percent-reads="48.94" position="chr12:115112055" protein-effect="A562V" status="unknown" strand="-" transcript="NM_016569">
          <dna-evidence sample="SQ-US1579280.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.4952" cds-effect="2143A&gt;G" depth="1246" equivocal="false" functional-effect="missense" gene="FLT3" percent-reads="49.52" position="chr13:28601289" protein-effect="T715A" status="unknown" strand="-" transcript="NM_004119">
          <dna-evidence sample="SQ-US1579280.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.5033" cds-effect="421C&gt;T" depth="1981" equivocal="false" functional-effect="missense" gene="FANCG" percent-reads="50.33" position="chr9:35078227" protein-effect="R141C" status="unknown" strand="-" transcript="NM_004629">
          <dna-evidence sample="SQ-US1579280.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.5192" cds-effect="224C&gt;T" depth="1273" equivocal="false" functional-effect="missense" gene="CSF1R" percent-reads="51.92" position="chr5:149460413" protein-effect="T75I" status="unknown" strand="-" transcript="NM_005211">
          <dna-evidence sample="SQ-US1579280.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.0021" cds-effect="731G&gt;A" depth="5314" equivocal="false" functional-effect="missense" gene="TP53" percent-reads="0.21" position="chr17:7577550" protein-effect="G244D" status="known" strand="-" transcript="NM_000546">
          <dna-evidence sample="SQ-US1579280.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.5055" cds-effect="1016C&gt;T" depth="1181" equivocal="false" functional-effect="missense" gene="NKX2-1" percent-reads="50.55" position="chr14:36986583" protein-effect="A339V" status="unknown" strand="-" transcript="NM_003317">
          <dna-evidence sample="SQ-US1579280.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.4727" cds-effect="64G&gt;A" depth="567" equivocal="false" functional-effect="missense" gene="BRAF" percent-reads="47.27" position="chr7:140624440" protein-effect="D22N" status="unknown" strand="-" transcript="NM_004333">
          <dna-evidence sample="SQ-US1579280.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.4887" cds-effect="649C&gt;T" depth="1240" equivocal="false" functional-effect="missense" gene="MLH1" percent-reads="48.87" position="chr3:37053562" protein-effect="R217C" status="unknown" strand="+" transcript="NM_000249">
          <dna-evidence sample="SQ-US1579280.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.4757" cds-effect="309C&gt;A" depth="1545" equivocal="false" functional-effect="missense" gene="TYRO3" percent-reads="47.57" position="chr15:41853737" protein-effect="S103R" status="unknown" strand="+" transcript="NM_006293">
          <dna-evidence sample="SQ-US1579280.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.0015" cds-effect="2267C&gt;A" depth="8024" equivocal="false" functional-effect="missense" gene="AR" percent-reads="0.15" position="chrX:66937413" protein-effect="T756N" status="unknown" strand="+" transcript="NM_000044">
          <dna-evidence sample="SQ-US1579280.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.0064" cds-effect="779A&gt;G" depth="6613" equivocal="false" functional-effect="missense" gene="PTEN" percent-reads="0.64" position="chr10:89717754" protein-effect="K260R" status="unknown" strand="+" transcript="NM_000314">
          <dna-evidence sample="SQ-US1579280.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.5102" cds-effect="4682T&gt;G" depth="2054" equivocal="false" functional-effect="missense" gene="MLL2" percent-reads="51.02" position="chr12:49439859" protein-effect="V1561G" status="unknown" strand="-" transcript="NM_003482">
          <dna-evidence sample="SQ-US1579280.01-1" />
        </short-variant>
      </short-variants>
      <copy-number-alterations />
      <rearrangements />
      <biomarkers>
        <microsatellite-instability status="MSS" />
        <tumor-mutation-burden score="1.26" status="low" unit="mutations-per-megabase" />
      </biomarkers>
      <non-human-content>
        <non-human organism="HHV-4" reads-per-million="65" status="unknown">
          <dna-evidence sample="SQ-US1579280.01-1" />
        </non-human>
        <non-human organism="HPV-16" reads-per-million="68" status="unknown">
          <dna-evidence sample="SQ-US1579280.01-1" />
        </non-human>
        <non-human organism="HHV-8" reads-per-million="29" status="unknown">
          <dna-evidence sample="SQ-US1579280.01-1" />
        </non-human>
        <non-human organism="HPV-6" reads-per-million="10" status="unknown">
          <dna-evidence sample="SQ-US1579280.01-1" />
        </non-human>
      </non-human-content>
    </variant-report>
  </rr:ResultsPayload>
</rr:ResultsReport>
